The Journal of Urology
Volume 183, Issue 2 , Pages 546-551 , February 2010

Impact of Hormonal Therapy on Intermediate Risk Prostate Cancer Treated With Combination Brachytherapy and External Beam Irradiation

  • Richard G. Stock

      Affiliations

    • Corresponding Author InformationCorrespondence: Department of Radiation Oncology, Mount Sinai School of Medicine, 1184 5th Ave., New York, New York 10025 (telephone: 212-241-7502; FAX: 212-410-7194)
    • ,
  • Swati Yamalachi
    • ,
  • Simon J. Hall
    • ,
  • Nelson N. Stone

      Affiliations

    • Financial interest and/or other relationship with Prologics, Nihon-MediPhysics, IsoAid and Prostate Cancer Educational Council.

Received 3 June 2009

References 

  1. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet. 2002;360:103
  2. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomized controlled trial. Lancet Oncol. 2005;6:841
  3. Pilepich MV, Winter K, John M, et al. Phase III Radiation Therapy Oncology group (RTOG) Trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Boil Phys. 2001;50:1243
  4. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long term results of Phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285
  5. D'Amico AV, Manola J, Loffredo M, et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer. JAMA. 2004;292:821
  6. Stock RG, Stone NN, Cesaretti JA, et al. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and post treatment biopsy results. Int J Radiat Oncol Biol Phys. 2006;64:527
  7. Stock RG, Cahlon O, Cesaretti JA, et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:1352
  8. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67
  9. Stone NN, Potter L, Davis BJ, et al. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys. 2007;69:1472
  10. Stock RG, Stone NN, Wesson MF, et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys. 1995;32:219
  11. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer; recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965
  12. Norusis MJ. SPSS 10.0 Guide to Data Analysis. 2000;Upper Saddle River: Prentice-Hall
  13. Stock RG, Stone NN, Iannuzzi C. Sexual potency following interactive ultrasound guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 1996;35:267
  14. Potters L, Torre T, Ashley R, et al. Examining the role of neoadjuvant deprivation in patients undergoing prostate brachytherapy. J Clin Oncol. 2000;18:1187
  15. Ash D, Al-Qaisieh B, Bottomley D, et al. The impact of hormone therapy on post-implant dosimetry and outcome following I-125 implant monotherapy for localized prostate cancer. Radiother Oncol. 2005;75:303
  16. Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate to high risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys. 2002;52:444
  17. Dattoli M, Wallner K, True L, et al. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer. 2007;110:551
  18. Merrick GS, Butler WM, Galbreath RW, et al. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk features?. BJU Int. 2003;91:23
  19. Martinez A, Galalae R, Gonzalez J, et al. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with high total radiation dose. J Urol. 2003;170:2296

 Study received institutional review board approval.

PII: S0022-5347(09)02641-X

doi: 10.1016/j.juro.2009.10.006

The Journal of Urology
Volume 183, Issue 2 , Pages 546-551 , February 2010

Article Tools

* Image Usage & Resolution